Boca Raton, Fla. — October 16, 2025 — Leads & Copy — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT, LIXTW) is prioritizing clinical execution and has confirmed advanced negotiations are underway to acquire complementary oncology assets, the company said. The clinical-stage pharmaceutical company is advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A). LIXTE outlined its fourth-quarter 2025 priorities and provided an update on its strategic business development and acquisition initiatives focused on oncology.
“LIXTE is entering Q4 with clear operational goals and a disciplined approach to strategic expansion,” said Geordan Pursglove, Chairman and Chief Executive Officer. “We remain focused on advancing LB-100 in high-need cancer indications, while pursuing acquisitions of complementary oncology assets that could enhance our pipeline, accelerate development and create durable value for patients and shareholders.”
The Company confirmed it is in advanced negotiations regarding potential transactions consistent with its strategy, although said there can be no assurance that any transaction will be completed.
2025 Progress and Q4 Priorities:
Clinical execution: Continued advancement of LB-100 across prioritized tumor settings, supported by growing clinical and preclinical evidence and collaborations with leading research centers.
Oncology-focused expansion: Active negotiation with synergistic or adjacent treatments, with the aim of building a differentiated, multi-asset oncology platform.
Operational readiness: Ongoing initiatives in quality, CMC, and regulatory alignment to support efficient study conduct and potential integration of acquired programs.
Contact Information:
info@lixte.com
General Phone: (631) 830-7092
Investor Phone: (888) 289-5533
PondelWilkinson Inc. Investor Relations: pwinvestor@pondel.com
Roger Pondel: (310) 279-5965
Laurie Berman: (310) 279-5962
Source: LIXTE Biotechnology Holdings, Inc.
